logowsbdaily | Tue, 24 May 2022 03:21:33 EST Where you find Tomorrow’s Hot Stocks Yesterday! 

NOT INVESTMENT ADVICE: ALL CONTENT IS PROVIDED 'AS IS' FOR ENTERTAINMENT AND/OR INFORMATIONAL PURPOSES ONLY.
WITHOUT WARRANTY OF ANY KIND. YOU BEAR ALL RISKS, INCLUDING ANY RELIANCE ON THE ACCURACY OF ANY INFORMATION.
WE ARE NOT AFFILIATED WITH THE WALLSTREETBETS NOR ANY OTHER COMMUNITY ON REDDIT.

Citius Pharmaceuticals, Inc.
(CTXR)

Citius Pharmaceuticals, Inc.
11 Commerce Drive
First Floor
Cranford, NJ 07016
United States
Citius Pharmaceuticals, Inc., a specialty pharmaceutical company, engages in the development and commercialization of critical care products focusing on anti-infective products in adjunct cancer care, prescription products, and mesenchymal stem cell therapy. The company is developing five proprietary products comprising Mino-Lok, an antibiotic lock solution to treat patients with catheter-related bloodstream infections by salvaging the infected catheter; Mino-Wrap, a liquifying gel-based wrap fo... Read More

Summary & Charts

Price$ 0.90-0.01 (-1.1%)
Day's Range$ 0.89 - 0.93 
Previous Close$ 0.91
Market Cap$ 133.6M USD
Short Interest %9.9 %As of Fri, 29 Apr 2022
Float133.72M
Outstanding146.03M
ExchangeNasdaqCM
IndustryBiotechnology
SectorHealthcare
Volume870.88K
Avg. Volume (20 day)2.04M
Rel. Volume (20 day)0.43
Rel. Volume (3 month)0.47
RatingBNeutral
DCFN/AStrong Buy
Debt/Equity8.16 %Neutral
ROE-5918446.34 %Strong Sell
ROA-5916982.91 %Strong Sell
P/E-0.00 %Neutral
P/B1.12 %Strong Buy
DateOpenHighLowCloseChangeVolumeR. Vol. (20d)R. Vol. (3m)Mentions
May 23, 2022$ 0.91$ 0.93$ 0.89$ 0.90-0.01870,8850.430.471
May 20, 2022$ 0.90$ 0.95$ 0.88$ 0.91+0.021,146,7870.540.62
May 19, 2022$ 0.90$ 0.91$ 0.87$ 0.89-0.01882,6550.420.47
May 18, 2022$ 0.94$ 0.95$ 0.89$ 0.90-0.05775,9050.340.41
May 17, 2022$ 0.90$ 0.96$ 0.90$ 0.95+0.061,107,7560.480.58
May 16, 2022$ 0.93$ 0.93$ 0.89$ 0.89-0.01950,6280.370.501
May 13, 2022$ 0.92$ 0.94$ 0.86$ 0.90-0.001,508,0620.590.811
May 12, 2022$ 0.89$ 0.95$ 0.88$ 0.90+0.022,425,0450.951.312
May 11, 2022$ 1.02$ 1.02$ 0.88$ 0.88-0.142,838,3041.151.562
May 10, 2022$ 0.97$ 1.02$ 0.95$ 1.02+0.081,633,0020.680.92
May 09, 2022$ 1.04$ 1.04$ 0.93$ 0.94-0.102,944,2281.231.671
May 06, 2022$ 1.01$ 1.14$ 0.98$ 1.04+0.075,090,7472.182.873
May 05, 2022$ 1.06$ 1.06$ 0.97$ 0.97-0.062,361,5571.051.37
May 04, 2022$ 1.03$ 1.06$ 0.96$ 1.03+0.011,382,0850.490.80
May 03, 2022$ 0.98$ 1.05$ 0.97$ 1.02+0.061,169,7690.420.681
May 02, 2022$ 1.00$ 1.02$ 0.90$ 0.96-0.052,544,7270.921.47
Apr 29, 2022$ 1.05$ 1.10$ 1.00$ 1.01-0.021,568,2440.590.91
Apr 28, 2022$ 0.96$ 1.05$ 0.94$ 1.03+0.122,763,3061.051.601
Apr 27, 2022$ 1.08$ 1.09$ 0.91$ 0.91-0.185,543,3222.193.252
Apr 26, 2022$ 1.10$ 1.14$ 1.08$ 1.09-0.021,208,0840.520.732

News

The latest news about Citius Pharmaceuticals, Inc. (CTXR).

PRNewsWire | 2022-05-18 09:30:00
CRANFORD, N.J. , May 18, 2022 /PRNewswire/ -- Citius Pharmaceuticals, Inc. ("Citius" or the "Company") (Nasdaq: CTXR), a late-stage biopharmaceutical company developing and commercializing first-in-class critical care products, today announced that it will present at the H.C.
InvestorPlace | 2022-05-08 09:00:38
These trending Reddit stocks have considerable growth catalysts in motion, offering healthy upside potential in May and beyond The post 3 Reddit Stocks to Buy in May appeared first on InvestorPlace. More From InvestorPlace Stock Prodigy Who Found NIO at $2… Says Buy THIS It doesn't matter if you have $500 in savings or $5 million.
PRNewsWire | 2022-04-14 09:25:00
CRANFORD, N.J. , April 14, 2022 /PRNewswire/ -- Citius Pharmaceuticals, Inc. ("Citius" or the "Company") (Nasdaq: CTXR), a late-stage biopharmaceutical company dedicated to the development and commercialization of first-in-class critical care products in oncology, anti-infectives in adjunct cancer care, unique prescription products, and stem cell therapies, today announced that it will present at NobleCon18, Noble Capital Markets' 18th Annual Investor Conference being held April 19-21, 2022.
Zacks Investment Research | 2022-04-07 11:18:16
Citius (CTXR) releases encouraging top-line data from the phase III study on I/ONTAK for the treatment of persistent or recurrent cutaneous T-cell lymphoma.
PennyStocks | 2022-04-06 09:31:45
Here's what you need to know about trading penny stocks on April 6th The post Trading Penny Stocks on April 6th, MOBQ Stock Pushes Up appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
Market Watch | 2022-04-06 08:14:39
Shares of Citius Pharmaceuticals Inc. CTXR, -1.60% were up 18.5% in premarket trading on Wednesday after the company shared positive topline data from a Phase 3 clinical trial for its experimental treatment for cutaneous T-cell lymphoma, which is a type of non-Hodgkin lymphoma. Citius said it plans to submit an application for approval of the investigational therapy, I/Ontak, to the Food and Drug Administration in the second half of this year based on this data.

Earnings

DateTimeEPS ExpectedEPS Reported%Revenue ExpectedRevenue Reported%
2022-05-12BMO-0.07-0.0528.58%------
2022-02-10BMO-0.06-0.06--19M----
2021-12-15BMO-0.04-0.0250%19M----
2021-08-12BMO-0.05-0.05--------
2021-05-13BMO-0.07-0.0442.86%------
2021-02-11BMO0.16-0.15-193.75%------
2020-08-14BMO-0.1-0.119.99%------
2020-05-14BMO-0.1-0.1330%------

Top Discussions

These are the top discussions over the last 24-hours that mention the CTXR stock ticker symbol.

Daily Plays May 23, 2022

Talk about your plays today or things you are on the lookout for. This is where you belong if your comment includes a $Ticker in that format. ​ *keep it civil please*...

67 comments | 0 votes


Failures to Deliver

Each point represents the aggregate net balance of shares that failed to be delivered as of a particular settlement date.

Please note that fails-to-deliver can occur for a number of reasons on both long and short sales. Therefore, fails-to-deliver are not necessarily the result of short selling, nor evidence of abusive “naked” short selling. For more information on short selling and fails-to-deliver, see Key Points About Regulation SHO, Division of Market Regulation, and Final Rule: Short Sales.

Last Updated: Tue, 14 Dec 2021 12:00 EST


Support & Feedback

Got feedback or suggestions for more awesomeness? Or wanna keep up to date with changes?

@wsbdaily@wsbdailywsbdaily subredditwsbdaily

No obligation, if you'd like to support us with development and hosting costs then

Buy Me A Coffee

Disclaimer

WE ARE NOT AFFILIATED WITH REDDIT, THE LEADERSHIP OR MODERATOR TEAMS OF ANY OF THE SUBREDDITS WE CRAWL NOR WITH ANY OTHER WEBSITE, COMPANY OR DATA PROVIDER FROM WHICH WE PULL AND/OR AGGREGATE DATA FROM.

ALL CONTENT ON THIS SITE IS SOLEY FOR ENTERTAINMENT AND/OR INFORMATIONAL PURPOSES ONLY. THE SITE AND CONTENT, ARE PROVIDED “AS IS” AND WITHOUT WARRANTY OF ANY KIND, EXPRESS OR IMPLIED. ANY CONTENT OR STATEMENT HEREIN SHOULD NOT BE CONSTRUED AS INVESTMENT ADVICE, OR AS AN OFFER TO BUY, SELL, OR SOLICIT THE PURCHASE OR SALE OF ANY SECURITY OR FINANCIAL INSTRUMENT. DO YOUR OWN DUE DILIGENCE.

THE INFORMATION ON THIS SITE IS NOT UPDATED IN REAL-TIME, EACH DATASET SPECIFIES WHEN IT WAS “LAST UPDATED”. MOST INFORMATION IS CURRENTLY INDEPENDENTLY PERIODICALLY UPDATED EVERY 30 TO 150 MINUTES AND ONLY WHEN THE MARKETS ARE CLOSED. YOU BEAR ALL RISKS ASSOCIATED WITH THE USE OF THE SITE AND CONTENT, INCLUDING WITHOUT LIMITATION, ANY RELIANCE ON THE ACCURACY, COMPLETENESS OR USEFULNESS OF ANY CONTENT AVAILABLE ON THE SITE. YOUR USE OF THE INFORMATION CONTAINED HEREIN IS SOLELY AT YOUR OWN RISK. DO YOUR OWN DUE DILIGENCE.

There are high risks associated with investing in securities. Investing in stocks, options, bonds, ETFs, mutual funds, and money market funds involve risk of substantial loss. Loss of principal is possible. Some high risk investments may use leverage, which will greatly accentuate any losses. Foreign investing involves special risks, including a greater volatility and political, economic and currency risks and differences in accounting methods. Any past investment performance is not a guarantee or predictor of future investment performance. DO YOUR OWN DUE DILIGENCE.

The software providing the content on this site is currently in an alpha state. Although care is taken to publish accurate data inaccurate information is very, very possible. Use at your own risk. DO YOUR OWN DUE DILIGENCE.